Lack of cytomegalovirus (CMV)-specific cell-mediated immune response using QuantiFERON-CMV assay in CMV-seropositive healthy volunteers: fact not artifact

被引:12
|
作者
Valle-Arroyo, Jorge [1 ]
Aguado, Rocio [1 ]
Paez-Vega, Aurora [1 ]
Perez, Ana B. [2 ]
Gonzalez, Rafael [3 ]
Fornes, Gema [4 ]
Torre-Cisneros, Julian [1 ,5 ]
Cantisan, Sara [1 ]
机构
[1] Univ Cordoba, Reina Sofia Univ Hosp, Inst Maimonides Invest Biomed Cordoba IMIBIC, Cordoba, Spain
[2] Reina Sofia Hosp, Dept Microbiol, Cordoba, Spain
[3] Reina Sofia Hosp, Dept Immunol, Cordoba, Spain
[4] Blood Transfus Ctr & Tissue & Cells Estab, Cordoba, Spain
[5] Reina Sofia Hosp, Infect Dis Unit, Cordoba, Spain
关键词
T-CELL; ORGAN TRANSPLANT; INFECTION; CD4(+); MEMORY; RISK; PROTECTION;
D O I
10.1038/s41598-020-64133-x
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The QuantiFERON-CMV (QF) assay measures cell-mediated immunity against cytomegalovirus (CMV-CMI), which is particularly useful in individuals susceptible to CMV infection such as transplant patients. A positive QF result identifies patients that are better protected against CMV infection. However, the significance of a negative QF result in CMV-seropositive individuals needs to be clarified. CMV-CMI was analyzed in healthy subjects using the QF assay, and, in parallel, the Flow-cytometric Assay of Specific Cell-mediated Immune response in Activated whole blood (FASCIA). FASCIA assay measures T-cell proliferation using CMV lysate as stimulus whereas QF assay use a mix of peptides. A total of 93 healthy volunteers were enrolled, and 13/71 CMV-seropositive individuals (18.3%) showed humoral/cellular discordance using QF assay (CMV+ QF-). Interestingly, with FASCIA assay CD4+ and CD8+ T-cell proliferations were lower in CMV+ QF- than in CMV+ QF+ individuals. Furthermore, CMV+ QF- volunteers had a lower level of anti-CMV IgG than CMV+ QF+ subjects. Discordant CMV+ QF- volunteers can be defined as low responder individuals since they show lower CMV-specific humoral and cellular immune responses in comparison to CMV+ QF+ individuals. Immune discordance shows the high heterogeneity of immunity to CMV in healthy subjects.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] CMV antigen-specific CD4+ and CD8+ T cell IFNγ expression and proliferation responses in healthy CMV-seropositive individuals
    Sinclair, E
    Black, D
    Epling, CL
    Carvidi, A
    Josefowicz, SZ
    Bredt, BM
    Jacobson, MA
    VIRAL IMMUNOLOGY, 2004, 17 (03) : 445 - 454
  • [22] MODULATORY EFFECTS OF CYTOMEGALOVIRUS (CMV) SPECIFIC HYPERIMMUNOGLOBULIN (CMVIG) ON CMV PROTEIN-MEDIATED ACTIVATION OF DIFFERENT EFFECTOR CELL POPULATIONS OF CELL-MEDIATED IMMUNITY
    Deml, Ludwig
    Koenig, Martin
    Schuettrumpf, Joerg
    Barabas, Sascha
    Cozzi, Emanuelle
    Grossi, Paolo
    TRANSPLANT INTERNATIONAL, 2017, 30 : 101 - 101
  • [23] Clinical Usefulness of Monitoring Cytomegalovirus-Specific Immunity by Quantiferon-CMV in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients
    Lee, Sae-Mi
    Kim, Yae-Jean
    Yoo, Keon Hee
    Sung, Ki Woong
    Koo, Hong Hoe
    Kang, Eun-Suk
    ANNALS OF LABORATORY MEDICINE, 2017, 37 (03) : 277 - 281
  • [24] High frequency of human cytomegalovirus (HCMV)-specific CD8+ T cells detected in a healthy CMV-seropositive donor
    Lang, KS
    Moris, A
    Gouttefangeas, C
    Walter, S
    Müller, M
    Wernet, D
    Hamprecht, K
    Rammensee, HG
    Stevanovic, S
    CELLULAR AND MOLECULAR LIFE SCIENCES, 2002, 59 (06) : 1076 - 1080
  • [25] High frequency of human cytomegalovirus (HCMV)-specific CD8+-T cells detected in a healthy CMV-seropositive donor
    K. S. Lang
    A. Moris
    C. Gouttefangeas
    S. Walter
    V. Teichgräber
    M. Müller
    D. Wernet
    K. Hamprecht
    H.-G. Rammensee
    S. Stevanovic
    Cellular and Molecular Life Sciences CMLS, 2002, 59 : 1076 - 1080
  • [26] The Impact of Pre- and Week 4 Post-Transplant CMV-Specific Elispot Assay on CMV Reactivation and Survival in CMV-Seropositive Allogeneic Hematopoietic Cell Transplant (Allo-HCT) Recipients
    Ariza-Heredia, Ella J.
    Shah, Dimpy P.
    Winston, Drew J.
    Rowley, Scott D.
    Mullane, Kathleen M.
    Chandrasekar, Pranatharthi
    Hari, Parameswaran
    Avery, Robin K.
    Peggs, Karl S.
    Kumar, Deepali
    Nath, Rajneesh
    Ljungman, Per T.
    Mossad, Sherif B.
    Dadwal, Sanjeet S.
    Cruikshank, William
    Chemaly, Roy F.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (03) : S47 - S48
  • [27] CYTOTOXIC CELL-MEDIATED IMMUNE (CMI) RESPONSES ASSOCIATED WITH CYTOMEGALOVIRUS (CMV) INFECTION AND FETAL WASTAGE
    HARRISON, CJ
    MYERS, MG
    PEDIATRIC RESEARCH, 1987, 21 (04) : A326 - A326
  • [28] Validation of the QuantiFERON-CMV Assay for Monitoring of Cytomegalovirus-Specific CD8+T-Cell Reconstitution in Pediatric Patients After Allogeneic Hematopoietic Stem Cell Transplantation
    Soldatou, A.
    Paouri, B.
    Paisiou, A.
    Avgerinou, G.
    Zisaki, K.
    Graphakos, S.
    Goussetis, E.
    JOURNAL OF CLINICAL IMMUNOLOGY, 2014, 34 : S498 - S499
  • [29] Clinical Assessment of Anti-Viral CD8+T Cell Immune Monitoring Using QuantiFERON-CMV® Assay to Identify High Risk Allogeneic Hematopoietic Stem Cell Transplant Patients with CMV Infection Complications
    Tey, Siok-Keen
    Kennedy, Glen A.
    Cromer, Deborah
    Davenport, Miles P.
    Walker, Susan
    Jones, Linda I.
    Crough, Tania
    Durrant, Simon T.
    Morton, James A.
    Butler, Jason P.
    Misra, Ashish K.
    Hill, Geoffrey R.
    Khanna, Rajiv
    PLOS ONE, 2013, 8 (10):
  • [30] CMV-seropositive recipients of CMV-seronegative allografts do not mount a pp65-antigen specific T-cell response during the first year post-transplant and are at very high risk for CMV-viraemia and disease
    Ganepola, S
    Hilbers, U
    Hartung, G
    Lange, T
    Liebert, UG
    Hofmann, J
    Niederwieser, D
    Uharek, L
    BONE MARROW TRANSPLANTATION, 2004, 33 : S23 - S24